INTRAOCULAR BEVACIZUMAB (AVASTIN) FOR CENTRAL AND BRANCH RETINAL VEIN OCCLUSION STUDY
Latest Information Update: 15 Jan 2018
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Branch retinal vein occlusion; Central retinal vein occlusion
- Focus Therapeutic Use
- 15 Jan 2018 New trial record